Antiglucocorticoid treatment of depression: Double-blind ketoconazole

Biological Psychiatry

Volumn 45, Issue 8, 1999, Pages 1070-1074

  Wolkowitz, Owen M ^a,b   Reus, Victor I ^a,b   Chan, Theresa ^a   Manfredi, Francesca ^a   Raum, William ^c   Johnson, Ron ^a   Canick, Jonathan ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Antiglucocorticoid; Cortisol; Dehydroepi androsterone (DHEA); Depression; Ketoconazole

Indexed keywords

GLUCOCORTICOID ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; PRASTERONE; PREGNENOLONE; PREGNENOLONE SULFATE; STEROID 11BETA MONOOXYGENASE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE;

ADRENAL CORTEX FUNCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HYDROCORTISONE RELEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 0033560686     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00267-4     Document Type: Article

References (25)

1. Amsterdam J., Mosley P.D., Rosenzweig M. Assessment of adrenocortical activity in refractory depression Steroid suppression with ketoconazole . Nolan W., Zohar J., Roose S., Amsterdam J. Refractory Depression. 1994;199-210 Wiley, Chichester.
2. Anand A., Malison R., McDougle C.J., Price L.H. Antiglucocorticoid treatment of refractory depression with ketoconazole A case report . Biol Psychiatry. 37:1995;338-340.
3. Checkley A.S., O'Dwyer A.M., Raven P., Taylor N., Lightman S. Antidepressant effects of treatments with metyrapone and hydrocortisone. Biol Psychiat. 35:1994;711.
4. Chouinard G., Belanger M.C., Beauclair L., Sultan S., Murphy B.E. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs A case report . Prog Neuropsychopharmacol Biol Psychiatry. 20:1996;1067-1079.
5. Fahey J.M., Pritchard G.A., Moltke L.L., et al. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther. 285:1998;271-276.
6. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Rev. 17:1996;187-205.
7. Iizuka H., Kishimoto A., Nakamura J., Mizukawa R. Clinical effects of cortisol synthesis inhibition on treatment-resistant depression. Nihon Shinkei Seishin Yakurigaku Zasshi. 16:1996;33-36.
8. Murphy B.E.P. Steroids and depression. J Steroid Biochem Molec Biol. 38:(5):1991;537-559.
9. Murphy B.E.P., Dhar V., Ghadirian A.M., Chouinard G., Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmocol. 11:1991;121-126.
10. Murphy B.E.P., Ghadirian A.M., Dhar V. Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Can J Psychiatry. 43:1998;279-286.
11. Murphy B.E.P., Wolkowitz O.M. The pathophysiologic significance of hypercorticism antiglucocorticoid strategies . Psychiat Ann. 23:1993;682-690.
12. O'Dwyer A.M., Lightman S.L., Marks M.N., Checkley S.A. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 33:1995;123-128.
13. Ravaris C., Sateia M.J., Beroza K.W., Noordsy D.L. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry. 45:1988;966-967.
14. Raven P.W., O'Dwyer A.M., Taylor N.F., Checkley S.A. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology. 21:1996;277-286.
15. Reus V.I., Wolkowitz O.M., Frederick S. Antiglucocorticoid treatments in psychiatry. Psychoneuroendocrinology. 22:(suppl):1997;S121-S124.
16. Ribeiro S.C.M., Tandon R., Grunhaus L., Greden J.F. The DST as a predictor of outcome in depression A meta-analysis . Am J Psychiatry. 150:1993;1618-1629.
17. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 317:1987;812-818.
18. Sovner R., Fogelman S. Ketoconazole therapy for atypical depression. J Clin Psychiatry. 57:1996;227-228.
19. Stalla G.K., Stalla J., von Werder K., et al. Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology. 155:1989;699-706.
20. Thakore J.H., Dinan T.G. Cortisol synthesis inhibition A new treatment strategy for the clinical and endocrine manifestations of depression . Biol Psychiatry. 37:1995;364-368.
21. Uzunova V., Sheline Y., Davis J.M., et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A. 95:1998;3239-3244.
22. Wolkowitz OM, Reus VI, Keebler A, et al (In press, 1999): Double-blind treatment of major depression with dehydroepiandrosterone (DHEA). Am J Psychiatry, in press.
23. Wolkowitz O.M., Reus V.I., Manfredi F., Ingbar J., Brizendine L. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry. 150:1993;810-812.
24. Wolkowitz O.M., Reus V.I., Roberts E., et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 41:1977;311-318.
25. Wolkowitz OM, Reus VI, Vinogradov S, et al (1966): Antiglucocorticoids in depression and schizophrenia. Presented at the Annual Conference of the American Psychiatric Association, New York, NY, May 7, 1966.